Ophthalmic statistics note 2: Absence of evidence is not evidence of absence by Bunce, C et al.
Ophthalmic statistics note 2:
absence of evidence is not
evidence of absence
SCENARIO 1
Patients undergoing vitrectomy surgery for idiopathic full-
thickness macular holes used to be routinely advised to follow a
strict regime of posturing face down for a variable period (up to
2 weeks) after surgery.1–3 There was a scientiﬁc rationale for this
—the tractional forces of gravity would force gases against the
macula allowing it to heal more readily. Patients who postured
were therefore believed to be less at risk of their macular hole
reopening and of the need for repeat surgery to repair the hole.
Medicine has clearly changed very signiﬁcantly over time with a
far greater emphasis on patient based outcomes and upon the
need for an evidence base to justify practice.4 5 A senior col-
league tells me that he has run a large randomised controlled
clinical trial on patients who have had vitrectomies for macular
holes. He states that the trial shows there is no difference in
failure rates between patients who spent a week posturing face
down after surgery and those who did not. He considers that
this trial means that it is now unethical to ask patients to
posture—particularly because several patients who did posture
fed back to him how uncomfortable they found posturing. I ask
him for a little more information about the trial and learn that
it was a randomised controlled clinical trial with larger numbers
of patients than typically found in ophthalmic surgical studies of
200 patients in each arm. Of those who spent a week posturing
face down, one required repeat surgery. Of those who did not,
two required repeat surgery. There is a published p value from a
Fisher’s exact test that was used to compare failure rates in the
two groups of 0.999 and what seems to me to be an entirely
cogent argument that this demonstrates no need for posturing
(see online supplementary appendix 1, table 1 for results of ana-
lysis). I have a persistent doubt however that something is not
quite right with this argument and the issue leaves me ponder-
ing somewhat. I decide to go back to grass roots and search the
internet for a deﬁnition of a p value.
The p value is the probability of obtaining the observed data or
data that were more extreme due to chance if the null hypothesis
were true.
I am somewhat perplexed by the term null hypothesis and
again resort to the internet.
The null hypothesis is the situation you believe exists (in this
scenario that the effect of interest is zero) and you perform a sig-
niﬁcance test to see whether there is sufﬁcient evidence for you
to reject the null hypothesis.
My interpretation of this in this scenario is that the null
hypothesis is that the risk of failure with posturing following
surgery is the same as the risk of failure with no posturing.
Continuing in this vein, if there truly is no difference between
the risks in the two groups the probability of observing the dif-
ference that I observed in this trial or something more extreme
(two failures in the non-posturing group vs one failure in the
posturing group) by chance alone is 0.999. I recall that p values
must lie between 0 and 1, with a value of 0 meaning impossible
and a value of 1 meaning absolute certainty. Here, a p value of
0.999 indicates that there is a very high chance that I would see
a difference in proportions of 2/200 versus 1/200 due to chance
alone and thus I have no evidence to reject the null hypothesis.
What does this mean? I have no evidence of a difference in
failure rates and thus no evidence to support the use of postur-
ing. Can I now simply advocate that it is safe for all patients not
to posture? Patients have reported that they do not enjoy postur-
ing, but the prospect of repeat surgery after an initial failure is
also very daunting.
DISCUSSION
This scenario is given to illustrate challenges faced when inter-
preting statistical non-signiﬁcance. Altman and Bland discuss
this issue in a paper entitled ‘Absence of evidence is not evi-
dence of absence’.6 Altman and Bland advocate that when pre-
sented with the statement ‘there is no evidence that’
consideration must be given as to whether absence of evidence
means that there is no information at all. They suggest estimat-
ing the effect with a Conﬁdence interval (CI) rather than simply
looking at p values. Figure 1 illustrates a simple ﬂow diagram
approach based on this. Table 1 illustrates the application of the
ﬂow diagram approach to Scenario 1. In the scenario given, the
odds of failure in posturing patients were 1/199, while those in
the non-posturing patients were 2/198. (Odds are commonly
seen in this context rather than risks, but for rare events, the
OR and relative risk are approximately equal). Clearly the odds
are slightly higher in the non-posturing group. The OR is 2
with a 95% CI of 0.18 to 22.3—see online supplementary
appendix 1, table 2 for the computation of this. The odds of
failure are estimated to be twice as common in the non-
posturing patients as in the posturing patients but the CI
Table 1 Application of flow diagram approach to Scenario 1
1. Research
question
Is posturing advisable in patients undergoing vitrectomy
surgery?
2. Null hypothesis There is no difference in risk of failure between patients
undergoing vitrectomy surgery in Group A (posturing) and
Group B (no posturing).
3. Result Odds in Group A=1/199
Odds in Group B=2/198
OR=2.02
95% CI=0.18 to 22.3
p=0.999
4. Interpretation The best estimate of the OR is 2, that is, failure is twice as
common in the non-posturing group as it is the posturing
group. There is however a lot of uncertainty with this
estimate. The trial data means that it is plausible that the
odds are the same in the two groups; however it is still
possible that the odds are actually more than 20 times in
the non-posturing group or as little as a fifth as high. If we
were to simply consider the p value none of this uncertainty
would be apparent and we would be far more tempted to
simply say that there is no evidence of a difference in failure
rates.
Figure 1 Flow diagram when presented with non-signiﬁcance.
Br J Ophthalmol May 2014 Vol 98 No 5 703
Education
indicates considerable uncertainty in this estimate. The data are
indeed consistent with there being no difference between the
two trial arms in that the CI includes an OR of 1 (no difference)
but the data are also consistent with the odds of failure in the
posturing arm being as much as 22 times the odds of failure in
the non-posturing arm (the upper limit of the CI) or indeed as
little as a ﬁfth as high. I feel much less conﬁdent now in stating
that there is no difference between the treatment arms and am
not sure that I entirely agree with my colleague about it being
unethical to ask patients to posture when there is so much
uncertainty in my estimate.
By computing a CI uncertainty is revealed which wasn’t
apparent when simply looking at a p value. So should patients
be posturing or not? The answer is currently unclear. What
hopefully is clear is that absence of evidence is not evidence of
absence and to assume that it is the case is unwise.
Most randomised trials wish to determine whether a treat-
ment is superior to the current standard treatment. However
non-inferiority and equivalence trials are becoming more
common in the medical literature.7 A non-inferiority trial seeks
to determine whether a new treatment is not worse than the
standard treatment by more than an acceptable amount (known
as the non-inferiority margin). An equivalence trial seeks to
determine whether a new treatment is therapeutically similar to
a standard treatment, that is, whether a new treatment differs
from the standard treatment by no more than the non-
inferiority margin. It is important to note that the term equiva-
lence has in the past been used in error to report negative
results of superiority studies—such trials often lacked statistical
power to rule out important differences.8 9 The trial conducted
by my colleague has not demonstrated equivalence as most clini-
cians and patients would consider an OR of 22.3 (which lies
within the CI) as an unacceptable difference, although deﬁning
the non-inferiority margin can present a real challenge to
researchers.
SCENARIO 2
The issue is of particular relevance when considering adverse
events. These may be rare yet catastrophic for the individuals
affected and their families. For treatments that are in widespread
use even small differences in risk can equate to sizeable numbers
of people and very large studies are needed to demonstrate
differences. The recent controversy regarding the use of
bevacizumab (Avastin) or ranibizumab (Lucentis) for the treat-
ment of age-related macular degeneration (AMD), the leading
cause of certiﬁable sight loss in the UK, very much centres
around the absence of evidence issue.10 Ranibizumab was
licensed for ocular use but costs substantially more than bevaci-
zumab which does not have a marketing authorisation in this
indication. Prior to licensing for AMD treatment, many people
chose to have treatment with bevacizumab since without any
treatment they faced rapid blindness and they preferred to
accept the possibility of increased side effects with the
unlicensed product. A large body of evidence built up as a result
of off license use, which suggested little evidence of harm
however this evidence was mostly from case series rather than
Level 1 evidence. The ABC study demonstrated that bevacizu-
mab was better than standard National Health Service (NHS)
care (prior to licensing of ranibizumab) and that it appeared to
offer similar beneﬁts to ranibizumab while not appearing to
increase harms.11 The study was not designed to have adequate
power to examine safety concerns and so failure to detect a dif-
ference should not equate to evidence of safety. The harms
under consideration were not trivial and included arteriothrom-
botic events and heart failure. Two large studies, inhibition of
VEGF in age-related choroidal neovascularisation (IVAN) and
comparison of age-related macular degeneration treatments trial
(CATT), have recently been reported, both of which suggest
that the drugs are indeed very similar with respect to harms and
safety, and calls to license bevacizumab for use in AMD in the
NHS have been made.12–14 IVAN and CATTwere conducted in
different parts of the world, yet the methodology was sufﬁ-
ciently similar to enable results from the two studies to be
validly combined using a technique called meta (Greek for after)
analysis.15 Recent pooling of results from the two studies has
suggested that a higher proportion of patients who receive beva-
cizumab experience one or more serious adverse events,
although numbers are small and so the jury is still out. Table 2
illustrates the application of the ﬂow diagram approach to
Scenario 2.
Catey Bunce,1 Krishna V Patel,1 Wen Xing,1 Nick Freemantle,2
Caroline J Doré,3 On behalf of the Ophthalmic Statistics Group
1NIHR Biomedical Research Centre at Moorﬁelds Eye Hospital NHS Foundation Trust
and UCL Institute of Ophthalmology, London, UK
2Department of Primary Care and Population Health, University College London,
London, UK
3UCL Clinical Trials Unit, University College London, London, UK
Correspondence to Dr Catey Bunce, NIHR Biomedical Research Centre at
Moorﬁelds Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology,
City Road, London, EC1V 2PD, UK; c.bunce@ucl.ac.uk
Lesson learnt Absence of evidence≠ Evidence of absence.
Collaborators The following additional members of the Ophthalmic Statistics
Group were given the opportunity to view the ﬁnal paper prior to submission and
provide suggestions and comments: Jonathan Cook, David Crabb, Phillippa
Cumberland, Gabriela Czanner, Paul Donachie, Andrew Elders, Marta Garcia-Fiñana,
Rachel Nash, Neil O’Leary, Toby Prevost, Chris Rogers, Luke Saunders, Selvaraj
Sivasubramanium, Irene Stratton, Joana Vasconcelos and Haogang Zhu.
Contributors CB drafted the paper. CB, KVP and WX reviewed and revised the
paper. CJD and NF conducted an internal peer review of the paper.
Competing interests The posts of CB, KVP and WX are partly funded by the
National Institute for Health Research (NIHR) Biomedical Research Centre based at
Moorﬁelds Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology.
The views expressed in this article are those of the authors and not necessarily
those of the NHS, the NIHR or the Department of Health.
Provenance and peer review Not commissioned; externally peer reviewed.
▸ Additional material is published online only. To view please visit the journal
online (http://dx.doi.org/10.1136/bjophthalmol-2013-304811).
Table 2 Application of flow diagram to Scenario 2
1. Research
question
For patients treated for age-related macular degeneration,
are SAEs more common on ranibizumab or bevacizumab?
A meta-analysis of the CATT and IVAN trials
2. Null
hypothesis
There is no difference in SAE risk between patients in Group
A (ranibizumab) and Group B (bevacizumab).
3. Result Odds of 1 or more SAE in bevacizumab=314/568
Odds of 1 or more SAE in ranibizumab=271/642
OR=0.76
95% CI=0.63 to 0.93
p=0.003
4. Interpretation Individual trial results: OR for IVAN trial=0.94 (95% CI 0.65
to 1.35) and OR for CATT trial=0.70 (95% CI 0.55 to 0.89).
The results of the meta-analysis indicate the need for
patients to be informed of the disparity in reported rates of
SAEs between the two drugs.
CATT, comparison of age-related macular degeneration treatments trial; IVAN,
inhibition of VEGF in age-related choroidal neovascularisation; SAE, serious adverse
event.
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